Myriad Genetics Inc. (MYGN) Tops Q3 EPS by 6c, Raises FY11 Guidance
Tweet Send to a FriendGet Alerts MYGN Hot Sheet
Trade MYGN Now!
Myriad Genetics Inc. (NASDAQ: MYGN) reported Q3 EPS of $0.31, $0.06 better than the analyst estimate of $0.25. Revenue for the quarter came in at $102.4 million versus the consensus estimate of $98.11 million.
Myriad Genetics Inc. sees FY2011 EPS of $1.06-$1.09, versus the consensus of $1.02. This is up from the company's previous guidance of $0.95-$1.00. Myriad Genetics Inc. sees FY2011 revenue of $396-$402 million, versus the consensus of $392 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Myriad Genetics Inc. sees FY2011 EPS of $1.06-$1.09, versus the consensus of $1.02. This is up from the company's previous guidance of $0.95-$1.00. Myriad Genetics Inc. sees FY2011 revenue of $396-$402 million, versus the consensus of $392 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wal-mart (WMT) Posts Q1 EPS of $1.14; U.S. Comps Down 1.4%; Guides Q2 EPS
- Cereplast, Inc. (CERP) Narrows Q1 Loss to 8c/Share
- Camtek Ltd (CAMT) Posts Q1 Loss of 1c/Share
Create E-mail Alert Related Categories
Earnings, Hot Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
